Idorsia Ltd (LON:0RQE)
United Kingdom · Delayed Price · Currency is GBP · Price in CHF | Market Cap | 1.01B +36.0% |
| Revenue (ttm) | 198.75M -5.3% |
| Net Income | -255.96M |
| EPS | -1.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 485.78 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,721 |
| Open | 4.226 |
| Previous Close | 4.156 |
| Day's Range | 4.104 - 4.226 |
| 52-Week Range | 2.815 - 7.550 |
| Beta | 1.68 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Idorsia
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial t... [Read more]
Financial Performance
In 2025, Idorsia's revenue was 220.58 million, an increase of 96.06% compared to the previous year's 112.51 million. Losses were -111.70 million, -57.65% less than in 2024.
Financial numbers in CHF Financial StatementsNews
Idorsia Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
QUVIVIQ is on track for CHF 200 million in 2026 sales, while pediatric development and a specialist-led TRYVIO/JERAYGO launch broaden growth prospects. Phase III readouts for cenerimod and selatogrel are expected in H1 next year.
Idorsia Transcript: Investor update
TRYVIO/JERAYGO launch plans target specialist centers and high-need patients, backed by CHF 120 million for 2027–2028 and expected cash-flow break-even in 2029. Daridorexant received FDA breakthrough designation for pediatric insomnia.
Idorsia Press release: Investor update
Idorsia issued a press release on November 4, 2026, disclosing material business information to investors.
Idorsia Slides: Investor update
Idorsia has posted slides in relation to its latest quarterly earnings report, which was published on November 4, 2026.
Idorsia Earnings release: Q3 2026
Idorsia released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Idorsia Quarterly report: Q3 2026
Idorsia has published its Q3 2026 quarterly earnings report on October 29, 2026.
Idorsia Slides: Investor presentation
Idorsia has posted slides in relation to its latest quarterly earnings report, which was published on October 28, 2026.
Idorsia price target raised to CHF 6 from CHF 5 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Idorsia (IDRSF) to CHF 6 from CHF 5 and keeps a Buy rating on the shares. The firm cites its improved long-term…
Idorsia price target raised to CHF 5.50 from CHF 4.50 at Deutsche Bank
Deutsche Bank analyst Henrietta Boeg raised the firm’s price target on Idorsia (IDRSF) to CHF 5.50 from CHF 4.50 and keeps a Hold rating on the shares. Published first on…
Idorsia Earnings Call Transcript: Q2 2026
QUVIVIQ sales surged 62% year-over-year to CHF 91 million, driven by strong EUCAN growth and a U.S. rebound. The company reaffirmed 2026 guidance, strengthened liquidity, and advanced its pipeline, with key launches and partnerships supporting future growth.
Idorsia Quarterly report: Q2 2026
Idorsia has published its Q2 2026 quarterly earnings report on July 30, 2026.
Idorsia Earnings release: Q2 2026
Idorsia released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Idorsia Slides: Q2 2026
Idorsia has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Idorsia Slides: Company presentation
Idorsia has posted slides in relation to its latest quarterly earnings report, which was published on July 30, 2026.
Idorsia price target raised to CHF 4.50 from CHF 4 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Idorsia (IDRSF) to CHF 4.50 from CHF 4 and keeps a Hold rating on the shares.
Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon
Ad hoc announcement pursuant to Art. 53 LR Senior secured term loan of up to CHF 250 million with a 5‑year maturity at a fixed 7% interest rate First tranche will fully refinance the existing New Mone...
Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology
Allschwil, Switzerland – June 1, 2026 Idorsia Ltd (SIX: IDIA) today announced additional positive clinical results for IDOR-1134-2831, its vaccine targeting Clostridioides difficile (C. difficile) in ...
New analysis of Idorsia's aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension
Allschwil, Switzerland – June 01, 2026 Idorsia Ltd (SIX: IDIA) announces new analyses from the Phase 3 PRECISION study demonstrating that aprocitentan, Idorsia's dual endothelin receptor antagonist, s...
Shareholders vote in favor of all proposals by the Board at Idorsia's Annual General Meeting 2026
Allschwil, Switzerland – May 6, 2026 At today's Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the Boa...
Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year
Ad hoc announcement pursuant to Art. 53 LR Preparation is underway to publish the strong pediatric daridorexant data and engage with regulatory authorities on next steps Co-promotion of QUVIVIQ is bei...
Idorsia Quarterly report: Q1 2026
Idorsia has published its Q1 2026 quarterly earnings report on April 28, 2026.
Idorsia Earnings release: Q1 2026
Idorsia released its Q1 2026 earnings on April 28, 2026, summarizing the period's financial results.
Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders
Allschwil, Switzerland – April 10, 2026 Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meetin...
Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development
Allschwil, Switzerland – April 9, 2026 Idorsia Ltd (SIX: IDIA) announces the appointment of Dr Amer Joseph as Executive Vice President, Chief Medical Officer (CMO) & Head of Global Clinical Developmen...
Idorsia Transcript: Study result
A phase II study in children with insomnia, including those with neurodevelopmental disorders, showed daridorexant significantly increased sleep time and improved morning alertness with a strong safety profile. The results suggest potential benefits beyond insomnia and support further regulatory discussions for pediatric and NDD indications.